Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LGH004
MIFTS: 47

Light Chain Deposition Disease

Categories: Rare diseases, Nephrological diseases, Blood diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Light Chain Deposition Disease

About this section

MalaCards integrated aliases for Light Chain Deposition Disease:

Name: Light Chain Deposition Disease 53 59
Light-Chain Deposition Disease 53
Light Chain Disease 73
Lcdd 59

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Nephrological diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare renal diseases
Rare haematological diseases


External Ids:

Orphanet 59 ORPHA93558
UMLS via Orphanet 74 C0238239
ICD10 via Orphanet 34 D89.8
UMLS 73 C0238239
Sources

Summaries for Light Chain Deposition Disease

About this section
NIH Rare Diseases : 53 Light chain deposition disease (LCDD) is a rare condition characterized by the deposition of specific proteins (monoclonal light chains) in the kidneys and other organs. Light chains are used to make antibodies that the body needs to fight infection. People with LCDD make too many light chains, which get deposited in many body tissues. While LCDD can occur in any organ, the kidneys are always involved. Signs and symptoms of LCDD may include protein in the urine; decreased kidney function; and/or nephrotic syndrome. Rarely, a person with LCDD may have symptoms from cardiac (heart) or liver involvement. The underlying cause of LCDD is unknown. It is often associated with multiple myeloma. LCDD may progress to multiple myeloma, or it may be present with multiple myeloma when it is first diagnosed. The goal of treating LCDD is to slow the production of light chains and their damage to organs. Treatment may include chemotherapy with a drug called Bortezomib; autologous stem cell transplantation; immunomodulatory drugs; and/or kidney transplant. If untreated, end-stage renal disease occurs in 70% of cases.

MalaCards based summary : Light Chain Deposition Disease, also known as light-chain deposition disease, is related to lacrimal duct defect and multicentric osteolysis, nodulosis, and arthropathy. An important gene associated with Light Chain Deposition Disease is MMP7 (Matrix Metallopeptidase 7), and among its related pathways/superpathways are Integrin Pathway and Degradation of the extracellular matrix. The drugs Mechlorethamine and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and heart, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia : 76 Light chain deposition disease (LCDD) is a rare blood cell disease which is characterized by deposition... more...

Sources

Related Diseases for Light Chain Deposition Disease

About this section

Diseases related to Light Chain Deposition Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Related Disease Score Top Affiliating Genes
1 lacrimal duct defect 11.6
2 multicentric osteolysis, nodulosis, and arthropathy 10.7 MMP14 MMP2
3 winchester syndrome 10.7 MMP14 MMP2
4 extracranial arteriovenous malformation 10.7 MMP2 MMP9
5 lentigo maligna melanoma 10.6 MMP2 MMP9
6 villous adenocarcinoma 10.6 MMP2 MMP9
7 psammomatous meningioma 10.6 MMP2 MMP9
8 brain glioblastoma multiforme 10.6 MMP7 MMP9
9 acute transverse myelitis 10.6 MMP2 MMP9
10 ischemic colitis 10.6 MMP2 MMP9
11 mid-dermal elastolysis 10.6 MMP12 MMP7
12 parotitis 10.6 MMP2 MMP9
13 pediatric multiple sclerosis 10.6 MMP7 MMP9
14 conjunctival nevus 10.6 MMP2 MMP9
15 microcystic meningioma 10.5 MMP2 MMP9
16 corneal ulcer 10.5 MMP2 MMP9
17 nasal cavity squamous cell carcinoma 10.5 MMP2 MMP9
18 transverse myelitis 10.5 MMP2 MMP9
19 sorsby fundus dystrophy 10.5 MMP2 MMP9
20 parotid gland cancer 10.4 MMP14 MMP7
21 lung giant cell carcinoma 10.4 MMP2 MMP9
22 amyloidosis 10.4
23 focal myositis 10.4 MMP2 MMP7 MMP9
24 senile ectropion 10.4 MMP2 MMP7 MMP9
25 myeloma, multiple 10.3
26 salivary gland cancer 10.3 MMP2 MMP7 MMP9
27 klatskin's tumor 10.3 MMP14 MMP2 MMP9
28 cryptogenic organizing pneumonia 10.3 MMP9 TNC
29 fibromatosis, gingival, 1 10.3 MMP1 MMP2
30 sialadenitis 10.3 MMP2 TNC
31 conjunctivochalasis 10.3 MMP1 MMP2
32 gliosarcoma 10.2 ACTC1 MMP2 MMP9
33 chronic actinic dermatitis 10.2 MMP1 MMP9
34 serous cystadenocarcinoma 10.2 MMP14 MMP2
35 chromoblastomycosis 10.2 MMP1 MMP9
36 actinic keratosis 10.1 MMP14 MMP2 TNC
37 lymphoma 10.1
38 retinitis 10.1
39 hepatitis 10.1
40 malignant giant cell tumor of soft parts 10.1 ACTC1 CD68
41 tongue cancer 10.0 MMP2 MMP9
42 nodular malignant melanoma 10.0 MMP1 MMP14 MMP2
43 al amyloidosis 10.0
44 chronic venous insufficiency 10.0 MMP1 MMP9
45 blepharochalasis 10.0 CD68 MMP9
46 lymphangioleiomyomatosis 10.0 MMP1 MMP14 MMP2
47 adult astrocytic tumour 10.0 MMP1 MMP7 MMP9
48 ischemic fasciitis 10.0 ACTC1 CD68
49 adenomyosis 10.0 MMP1 MMP2 MMP9
50 odontogenic myxoma 10.0 MMP1 MMP2 MMP9

Graphical network of the top 20 diseases related to Light Chain Deposition Disease:



Diseases related to Light Chain Deposition Disease
Sources

Symptoms & Phenotypes for Light Chain Deposition Disease

About this section

MGI Mouse Phenotypes related to Light Chain Deposition Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.56 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
2 immune system MP:0005387 9.17 CD68 MMP1 MMP12 MMP14 MMP2 MMP7
Sources

Drugs & Therapeutics for Light Chain Deposition Disease

About this section

Drugs for Light Chain Deposition Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
2
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
3
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 179324-69-7 387447 93860
4
Melphalan Approved Phase 3,Phase 2,Not Applicable 148-82-3 4053 460612
5
Lenalidomide Approved Phase 3 191732-72-6 216326
6 Dexamethasone acetate Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
7 Alkylating Agents Phase 3,Phase 2
8 glucocorticoids Phase 3,Phase 2,Phase 1,Not Applicable
9
protease inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
10 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
11 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
12 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
13 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
14 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
15 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
17 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
18 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
19 Anti-Infective Agents Phase 3,Phase 2,Phase 1
20 Antiemetics Phase 3,Phase 2,Phase 1,Not Applicable
21 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
22 BB 1101 Phase 3,Phase 2,Phase 1,Not Applicable
23 Autonomic Agents Phase 3,Phase 2,Phase 1,Not Applicable
24 Antineoplastic Agents, Alkylating Phase 3,Phase 2
25 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
26 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
27 phenylalanine Nutraceutical Phase 3,Phase 2
28
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
29
Etoposide Approved Phase 2 33419-42-0 36462
30
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
31
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
32
Cyclophosphamide Approved, Investigational Phase 2,Not Applicable 50-18-0, 6055-19-2 2907
33
Lenograstim Approved, Investigational Phase 2 135968-09-1
34
Doxil Approved June 1999 Phase 2 31703
35 interferons Phase 2
36 Interferon-alpha Phase 2
37 Antiviral Agents Phase 2
38 Myeloma Proteins Phase 2,Not Applicable
39 Topoisomerase Inhibitors Phase 2
40 Dexamethasone 21-phosphate Phase 2
41 Paraproteins Phase 2,Not Applicable
42 Antibiotics, Antitubercular Phase 2
43 Antibodies Phase 2,Not Applicable
44 Immunoglobulins Phase 2,Not Applicable
45 Etoposide phosphate Phase 2
46 Antirheumatic Agents Phase 2
47 Antineoplastic Agents, Phytogenic Phase 2
48 Adjuvants, Immunologic Phase 2
49
Sunitinib Approved, Investigational Phase 1 341031-54-7, 557795-19-4 5329102
50 Pomalidomide Approved Phase 1 19171-19-8

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Completed NCT01078454 Phase 3 melphalan;dexamethasone;bortezomib
2 Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Active, not recruiting NCT01169337 Phase 3 Lenalidomide
3 S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis Completed NCT00002849 Phase 2 dexamethasone
4 Bortezomib With Melphalan and Prednisone for Multiple Myeloma Completed NCT00734149 Phase 2 Bortezomib;Melphalan;Prednisone
5 Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease Active, not recruiting NCT00520767 Phase 2 bortezomib;dexamethasone;melphalan
6 Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma Active, not recruiting NCT01849783 Phase 2 dexamethasone;cisplatin;doxorubicin;cyclophosphamide;etoposide;bortezomib;thalidomide;melphalan
7 HD Melphalan and SCT in Patients With IGDD or LCDD Terminated NCT00681044 Phase 2 melphalan
8 Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed NCT01533194 Phase 1
9 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1 sunitinib malate
10 First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD Suspended NCT01728259 Phase 1 pomalidomide;bortezomib;dexamethasone
11 Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis Active, not recruiting NCT01383759 Not Applicable Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
12 Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects Terminated NCT01018927

Search NIH Clinical Center for Light Chain Deposition Disease

Sources

Genetic Tests for Light Chain Deposition Disease

About this section
Sources

Anatomical Context for Light Chain Deposition Disease

About this section

MalaCards organs/tissues related to Light Chain Deposition Disease:

41
Kidney, Liver, Heart, Lung, B Cells, Skin, Brain
Sources

Publications for Light Chain Deposition Disease

About this section

Articles related to Light Chain Deposition Disease:

(show top 50) (show all 176)
# Title Authors Year
1
Light Chain Deposition Disease with Bullous Skin Lesions Mimicking Atypical Bullous Pemphigoid. ( 29135016 )
2018
2
Successful treatment of nephrotic syndrome induced by lambda light chain deposition disease using lenalidomide: A case report andA review of the literaturea8c. ( 29393843 )
2018
3
Light Chain Deposition Disease Associated With Multiple Myeloma Developing in Late Pregnancy. ( 29507277 )
2018
4
Detection and Treatment of Monoclonal Gammopathy of Renal Significance With Progression to Light Chain Deposition Disease. ( 28809601 )
2017
5
Primary CNS Nonamyloidogenic Light Chain Deposition Disease: Case Report and Brief Review. ( 28669250 )
2017
6
Primary Central Nervous System Lymphoma With Light Chain Deposition Disease (Aggregoma). ( 29280764 )
2017
7
Light Chain Deposition Disease Diagnosed with Laser Micro-dissection, Liquid Chromatography, and Tandem Mass Spectrometry of Nodular Glomerular Lesions. ( 28050001 )
2017
8
Cardiac light-chain deposition disease relapsing in the transplanted heart. ( 28562083 )
2017
9
Cutaneous Light Chain Deposition Disease: A Report of 2 Cases and Review of the Literature. ( 28953013 )
2017
10
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. ( 28383130 )
2017
11
Treatment of idiopathic light chain deposition disease: complete remission with bortezomib and dexamethasone. ( 28001187 )
2016
12
Surgical Management of Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Associated With Light-Chain Deposition Disease. ( 27211983 )
2016
13
Spontaneous splenic rupture in a patient with light-chain deposition disease undergoing autologous peripheral blood stem cell transplantation. ( 27384856 )
2016
14
A Case of Cardiac Light Chain Deposition Disease in a Patient with Solitary Plasmacytoma. ( 26988342 )
2016
15
Five Sequential Evaluations of Renal Histology in a Patient with Light Chain Deposition Disease. ( 27746438 )
2016
16
Nodular pulmonary light chain deposition disease. ( 27306574 )
2016
17
Clinicopathological characteristics and outcomes of light chain deposition disease: an analysis of 48 patients in a single Chinese center. ( 27056200 )
2016
18
Can We Cure Light Chain Deposition Disease of the Kidneys?-A Review and Case Report of a Patient Treated With a Triple Transplant Approach. ( 27101986 )
2016
19
Animal Models of Light Chain Deposition Disease Provide a Better Understanding of Nodular Glomerulosclerosis. ( 26794829 )
2016
20
Intracystic hemorrhage in a patient with pulmonary cystic disorder related to light-chain deposition disease. ( 27756655 )
2016
21
Light Chain Deposition Disease After Kidney Transplantation With Long Graft Survival: Case Report. ( 26915878 )
2016
22
ATYPICAL MACULOPATHY IN A PATIENT WITH LIGHT CHAIN DEPOSITION DISEASE MIMICKING ADVANCED GEOGRAPHIC ATROPHY. ( 26934302 )
2016
23
Unusual case of light chain deposition disease kappa restricted in a case of multiple myeloma. ( 27728483 )
2016
24
Nodular pulmonary light chain deposition disease: an entity associated with SjAPgren syndrome or marginal zone lymphoma. ( 26502747 )
2016
25
Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male. ( 28083151 )
2016
26
Light Chain Deposition Disease in an Older Adult Patient Successfully Treated with Long-term Administration of Bortezomib, Melphalan and Prednisone. ( 27181540 )
2016
27
OCULAR MANIFESTATIONS OF MONOCLONAL IMMUNOGLOBULIN LIGHT CHAIN DEPOSITION DISEASE. ( 27315323 )
2016
28
Bortezomib Based Chemotherapy for Light Chain Deposition Disease. ( 27762125 )
2016
29
A case of light chain deposition disease in kidney in a known case of multiple myeloma. ( 27728501 )
2016
30
Unusual Presentation of Light Chain Deposition Disease: A Case Report. ( 27437235 )
2016
31
ENHANCED DEPTH IMAGING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY FEATURES OF LIGHT CHAIN DEPOSITION DISEASE. ( 26398301 )
2015
32
Natural history and outcome of light chain deposition disease. ( 26392598 )
2015
33
Light-Chain Deposition Disease Successfully Treated with Bortezomib in an Elderly Patient: A Case Report and Review of the Literature. ( 26568005 )
2015
34
AJKD Atlas of Renal Pathology: Light Chain Deposition Disease. ( 26593321 )
2015
35
Clinical and Prognostic Differences among Patients with Light Chain Deposition Disease, Myeloma Cast Nephropathy and Both. ( 25860232 )
2015
36
Pulmonary light-chain deposition disease: CT and pathology findings in nine patients. ( 25659938 )
2015
37
Enlightening light chain deposition disease. ( 26705338 )
2015
38
Monoclonal gammopathy of renal significance with light-chain deposition disease diagnosed postrenal transplant: a diagnostic and therapeutic challenge. ( 25441103 )
2015
39
Blood stem cell transplantation to treat cystic lung light chain deposition disease. ( 26160867 )
2015
40
Nonamyloid tumoral light-chain-deposition disease (aggregoma) of the paraspinal region. ( 26253133 )
2015
41
Education and imaging. Hepatobiliary and Pancreatic: Portal hypertension due to hepatic light chain deposition disease. ( 24832781 )
2014
42
Osteolytic femoral lesion detected by sonography in a case of light chain deposition disease. ( 24449208 )
2014
43
Isolated intracerebral light chain deposition disease: novel imaging and pathologic findings. ( 25084689 )
2014
44
Light chain deposition disease without glomerular proteinuria: a diagnostic challenge for the nephrologist. ( 24619059 )
2014
45
Late recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: a case report. ( 25249814 )
2014
46
Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach? ( 25022598 )
2014
47
Hypertension, renal failure, and edema in a 38-year-old man: light chain deposition disease; a case report and review of the literature. ( 24772399 )
2014
48
Light chain deposition disease and proximal tubulopathy in two successive kidney allografts. ( 25492671 )
2014
49
Sudden death possibly related to lenalidomide given for cardiac and muscle AL amyloidosis secondary to light chain deposition disease. ( 22504167 )
2013
50
Serous retinal detachments associated with light chain deposition disease. ( 25391113 )
2013
Sources

Variations for Light Chain Deposition Disease

About this section
Sources

Expression for Light Chain Deposition Disease

About this section
Search GEO for disease gene expression data for Light Chain Deposition Disease.
Sources

Pathways for Light Chain Deposition Disease

About this section

Pathways related to Light Chain Deposition Disease according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Integrin Pathway 64
Show member pathways
 13.13 MMP1 MMP12 MMP2 MMP7 MMP9 TNC
2
Degradation of the extracellular matrix 66
Show member pathways
 12.46 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
3
TGF-beta Signaling Pathway (WikiPathways) 1
11.85 MMP1 MMP12 TNC
4
Colorectal Cancer Metastasis 64
11.85 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
5
Adhesion 4
11.8 MMP14 MMP2 MMP9
6
Interleukin-4 and 13 signaling 66
11.76 MMP1 MMP2 MMP9
7
Angiogenesis (CST) 4
11.65 MMP2 MMP7 MMP9 TNC
8
Bladder cancer 37 1
11.53 MMP1 MMP2 MMP9
9
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.45 MMP1 MMP2 MMP9
10
AGE/RAGE pathway 1
11.44 MMP14 MMP2 MMP7 MMP9
11
Matrix Metalloproteinases 1
Show member pathways
 11.43 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
12
amb2 Integrin signaling 1
11.29 MMP2 MMP9
13
Osteopontin-mediated events 1
Show member pathways
 11.25 MMP2 MMP9
14
Cell adhesion_Cell-matrix glycoconjugates 22
11.22 MMP1 MMP9 TNC
15
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.14 MMP1 MMP2 MMP9
16
A-beta Pathways: Uptake and Degradation 65
11.1 MMP2 MMP9
17
Syndecan-4-mediated signaling events 1
11.08 MMP9 TNC
18
Plasma membrane estrogen receptor signaling 1
10.99 MMP2 MMP9
19
A-beta Pathways: Plaque Formation and APP Metabolism 65
10.93 MMP2 MMP9
20
Cell adhesion_ECM remodeling 22
10.89 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
21
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 66
10.88 MMP1 MMP2
22
Syndecan-1-mediated signaling events 1
10.77 MMP1 MMP7 MMP9
Sources

GO Terms for Light Chain Deposition Disease

About this section

Cellular components related to Light Chain Deposition Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.76 IGKC IGKV1-5 MMP1 MMP12 MMP2 MMP7
2 extracellular space GO:0005615 9.56 ACTC1 IGKC MMP12 MMP14 MMP2 MMP7
3 blood microparticle GO:0072562 9.43 ACTC1 IGKC IGKV1-5
4 extracellular matrix GO:0031012 9.17 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9

Biological processes related to Light Chain Deposition Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.76 IGKC IGKV1-5 MMP1 MMP12 MMP14 MMP2
2 leukocyte migration GO:0050900 9.62 IGKC IGKV1-5 MMP1 MMP9
3 cellular protein metabolic process GO:0044267 9.54 MMP1 MMP2 TNC
4 embryo implantation GO:0007566 9.43 MMP2 MMP9
5 endodermal cell differentiation GO:0035987 9.43 MMP14 MMP2 MMP9
6 extracellular matrix disassembly GO:0022617 9.43 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
7 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.4 MMP2 MMP9
8 collagen catabolic process GO:0030574 9.1 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9

Molecular functions related to Light Chain Deposition Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.88 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
2 zinc ion binding GO:0008270 9.8 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
3 peptidase activity GO:0008233 9.73 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
4 metallopeptidase activity GO:0008237 9.63 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
5 endopeptidase activity GO:0004175 9.54 MMP1 MMP12 MMP9
6 metalloendopeptidase activity GO:0004222 9.43 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
7 serine-type endopeptidase activity GO:0004252 9.23 IGKC IGKV1-5 MMP1 MMP12 MMP14 MMP2
Sources

Sources for Light Chain Deposition Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....